Poland· PL-100178657
Rasilez
A aliskiren product containing aliskirenum, registered in Poland by Noden Pharma DAC. The same ATC class is registered in 13 of our 19 countries.
Checked against URPL (Poland) on
Informational only — not a medical device.
Where it is registered
Aliskiren is registered in 13 of 19 countries.
Countries holding a registration under ATC C09XA02 (aliskiren), each read from that country’s own register.
- This record: Poland, from URPL (Poland)
- 9 of them publish a price we can compare per daily dose
Aliskiren · ATC C09XA02
13 / 19 countries
- Belgiumprice
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Italyprice
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of aliskiren costs, country by country.
Normalised to the WHO defined daily dose (0.15 g), the median price runs from $0.95 in Italy to $3.43 in United States — a ×3.6 gap.
- 2 markets with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
- US figures are pharmacy acquisition cost (CMS NADAC), not retail
Aliskiren · price per daily dose (0.15 g)
USD · FX 28 Sept 2026
- US United States$3.43 (acquisition cost)
- IT Italy$0.95
The record
At a glance
URPL (Poland)- Active substance
- Aliskirenum
- Manufacturer
- Noden Pharma DAC
- Country
- Poland (PL)
- ATC code
- C09XA02
- ATC class
- Aliskiren
- Defined daily dose
- 0.15 g, O
- Reimbursed
- Not published by this register
- Source register
- URPL (Poland)
- Last checked
- September 27, 2026
Packs & prices · 4
- gtin05909990066506
- gtin05909990066520
- gtin05909990066537
- gtin05909990066544
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
227 interactions on record for aliskiren.
Graded by severity as the source publishes them — 1 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Aliskiren · interactions on record
227 records
- 1 severe
- 147 moderate
- 26 info
Most severe, free to view
- CiclosporinL04AD01severe
- ClotrimazoleA01AB18moderate
- AprepitantA04AD12moderate
- RolapitantA04AD14moderate
53 more interactions with mechanism and management, from a commercially licensed source.
Sign in to check- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Aliskiren in 9 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- SpainRASILEZ 300 mg COMPRIMIDOS RECUBIERTOS CON PELICULANovartis Europharm Limited
- SwitzerlandRasilez 300 mg, FilmtablettenFuture Health Pharma GmbH
- IcelandRasilezNoden Pharma DAC
- NetherlandsRasilez 300 mg, filmomhulde tabletNoden Pharma DAC
- SwedenRasilez 300 mg Filmdragerad tablettLXO Ireland DAC
- United StatesALISKIRENEndo USA, Inc.
- United KingdomRasilez 150mg tabletsWaymade Healthcare Plc
- NorwayRasilezNoden Pharma
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Rasilez
- Liechtenstein · Rasilez
- Norway · Rasilez
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/b6d9a4f7-e309-4b13-8026-bf3cd057792d GET /v1/drugs/b6d9a4f7-e309-4b13-8026-bf3cd057792d?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Tabletki powlekane",
"source": "urpl",
"strength": "300 mg",
"packaging": "05909990066506 ¦ Rp ¦ Skasowane ¦ EU/1/07/405/011 ¦ 20374\n7 tabl.\n05909990066520 ¦ Rp ¦ EU1/07/405/031 ¦ 55944\n14 tabl.\n05909990066537 ¦ Rp ¦ EU/1/07/405/032 ¦ 55945\n28 tabl.\n05909990066544 ¦ Rp ¦ EU/1/07/405/035 ¦ 55946\n56 tabl.\nRp ¦ EU/1/07/405/033 ¦ 105176\n30 tabl.\nRp ¦ EU/1/07/405/034 ¦ 105177\n50 tabl.\nRp ¦ EU/1/07/405/036 ¦ 105178\n56 tabl. (56 x 1)\nRp ¦ Skasowane ¦ EU/1/07/405/017 ¦ 105179\n84 tabl. (3x28)\nRp ¦ Skasowane ¦ EU/1/07/405/018 ¦ 105180\n90 tabl. (3 x 30)\nRp ¦ EU/1/07/405/037 ¦ 105181\n90 tabl.\nRp ¦ EU/1/07/405/038 ¦ 105182\n98 tabl.\nRp ¦ Skasowane ¦ EU/1/07/405/019 ¦ 105183\n98 tabl. (2x49)\nRp ¦ EU/1/07/405/039 ¦ 105184\n98 tabl. (2 x 49 x 1)\nRp ¦ EU/1/07/405/040 ¦ 105185\n280 tabl. (20 x 14)",
"substance": "Aliskirenum 300 mg",
"common_name": "Aliskirenum",
"pl_product_id": "100178657",
"pozwolenie_nr": null,
"auth_procedure": "CEN",
"authorisation_validity": null
}See everything about aliskiren.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.